- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04517474
Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use. (CANREDUCE)
Evaluación de Una Herramienta E-Salud Para la reducción Del Consumo de Cannabis
Cannabis is the most widely used psychoactive substance around the world after alcohol and tobacco. Although approximately one in ten users develop serious problems of dependency, only a small number attend outpatient addiction counseling centers. CANreduce is an adherence-focused guidance enhanced web-based self-help program with promising results in German and other languages. It also reaches those users who hesitate to approach such treatment centers and help them to reduce their cannabis use.
This study will test the effectiveness of the Spanish version of the enhanced web-based self-help intervention with psychological support, an enhanced web-based self-help intervention (without psychological support) and a waiting list control in reducing cannabis use in problematic users.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marta Torrens, PhD
- Phone Number: 1697 0034933160697
- Email: mtorrens@imim.es
Study Contact Backup
- Name: Juan-Ignacio Mestre-Pinto, PhD
- Phone Number: 0034933160697
- Email: jmestre@imim.es
Study Locations
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08003
- Recruiting
- Juan-Ignacio Mestre-Pinto
-
Contact:
- Juan-Ignacio Mestre-Pinto, PhD
- Email: jmestre@imim.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cannabis use of at least once a week 30 days prior to study entry
- At least 18 years old
- At least weekly internet access and a valid email address
Exclusion Criteria:
- Participant reports current pharmacological psychiatric disease or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal or homicidal thoughts
- Use of other pharmacological and psychosocial treatments for cannabis use disorders
- Inability to read or write in Spanish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: CANreduce with psychological support
Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
|
CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence.
It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying "no" to foster refusal skills, Dealing with burdens, Preserving achievements).
Participants can study all modules at their own pace and order, though a specific order will be advised.
Other Names:
psychological support
|
|
EXPERIMENTAL: CANreduce without psychological support
Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
|
CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence.
It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying "no" to foster refusal skills, Dealing with burdens, Preserving achievements).
Participants can study all modules at their own pace and order, though a specific order will be advised.
Other Names:
|
|
NO_INTERVENTION: Treatment as usual
Users will be prompt to a web with a list of the treatment centers nearby their postal code
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the number of days of self-reported cannabis use in the past 30 days (TLFB)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
Participants enter their cannabis consumption frequency into their consumption diary every week. More days of self-reported cannabis use indicate worse state |
Baseline, 6, 12 and 24 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the number of days of weekly self-reported cannabis use Time Life Follow Back (TLFB)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
Participants enter their cannabis consumption frequency into their consumption diary every week. More days of self-reported cannabis use indicate a worse outcome |
Baseline, 6, 12 and 24 weeks.
|
|
Change in the quantity of weekly standard joints (TLFB with predifined cannabis standard joints)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
Participants enter their cannabis consumption quantity into their consumption diary every week. More number of weekly standard joints indicate a worse outcome |
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
CUDIT-R was developed containing 8 items, two each from the domains of consumption, cannabis problems (abuse), dependence, and psychological features. It has excellent psychometric properties. High sensitivity (91%) and specificity (90%). This questionnaire was designed for self administration and is scored by adding each of the 8 items:
Higher scores indicate a worse outcome |
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the Severity Dependence Scale (SDS)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
SDS is a standard instrument to assess the severity to any drug dependence.
Each of the five items is scored on a 4-point scale (0-3).
The total score is obtained through the addition of the 5-item ratings (0-15).
The higher the score the higher the level of dependence.
|
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the Alcohol Use Disorders Identification Test (AUDIT)
Time Frame: Baseline, 6, 12 and 24 weeks.
|
AUDIT is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
Each item scores 0-4, The total score ranges from 0-40.
A score of 8 or more is considered to indicate hazardous or harmful alcohol use.
The AUDIT has been validated across genders and in a wide range of racial/ethnic groups and is well suited for use in primary care settings.
Higher scores indicate a worse outcome
|
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the PROMIS Emotional Distress - Depression - Short Form 8b
Time Frame: Baseline, 6, 12 and 24 weeks.
|
PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured. 8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome |
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the PROMIS Anxiety 8a - Adult v1.0
Time Frame: Baseline, 6, 12 and 24 weeks.
|
PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured. 8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome |
Baseline, 6, 12 and 24 weeks.
|
|
Change in the scoring of the EQ-5D-5L
Time Frame: Baseline, 6, 12 and 24 weeks.
|
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Score ranges from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health), The second part of the questionnaire consists of a visual analogue scale (VAS) on which the patient rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health). |
Baseline, 6, 12 and 24 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marta Torrens, PhD, Hospital del Mar Research Institute (IMIM)
Publications and helpful links
General Publications
- Amann M, Haug S, Wenger A, Baumgartner C, Ebert DD, Berger T, Stark L, Walter M, Schaub MP. The Effects of Social Presence on Adherence-Focused Guidance in Problematic Cannabis Users: Protocol for the CANreduce 2.0 Randomized Controlled Trial. JMIR Res Protoc. 2018 Jan 31;7(1):e30. doi: 10.2196/resprot.9484.
- Schaub MP, Wenger A, Berg O, Beck T, Stark L, Buehler E, Haug S. A Web-Based Self-Help Intervention With and Without Chat Counseling to Reduce Cannabis Use in Problematic Cannabis Users: Three-Arm Randomized Controlled Trial. J Med Internet Res. 2015 Oct 13;17(10):e232. doi: 10.2196/jmir.4860.
- Mestre-Pinto JI, Fonseca F, Schaub MP, Baumgartner C, Alias-Ferri M, Torrens M. CANreduce-SP-adding psychological support to web-based adherence-focused guided self-help for cannabis users: study protocol for a three-arm randomized control trial. Trials. 2022 Jun 22;23(1):524. doi: 10.1186/s13063-022-06399-2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/8901/I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use Disorder
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingMarijuana Abuse | Marijuana Use | Addiction | Substance Use | Cannabis Dependence | Substance Use Disorders | Cannabis Use | Substance Abuse | Addiction, Substance | Marijuana Dependence | Substance Dependence | Marijuana Smoking | Cannabis Abuse | Cannabis Use Disorder | Marijuana | Cannabis Intoxication | Substance Related... and other conditionsUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Recruiting
-
Brigham and Women's HospitalNot yet recruitingCannabis Use Disorder
-
Anders Fink-Jensen, MD, DMSciNeurobiology Research Unit, RigshospitaletRecruitingCannabis Dependence | Cannabis Abuse | Cannabis Use Disorder | Cannabis Use Disorders | Cannabis AddictionDenmark
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingTobacco Use Disorder | Marijuana Use | Tobacco Use Cessation | Cannabis Use | Cannabis Use DisorderUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
McMaster UniversityCenter for Medicinal Cannabis Research; Peter Boris Centre for Addictions Research...RecruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereCanada
-
Boston Children's HospitalNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use | Cannabis Use Disorder | Cannabis IntoxicationUnited States